[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

Johannes H. A. M. Kaanders*, Johan Bussink, Erik H. J. G. Aarntzen, P. tra Braam, Heidi Rütten, Richard W. M. van der Maazen, Marcel Verheij, Sven van den Bosch

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.
Original languageEnglish
JournalSeminars in Radiation Oncology
Early online date2023
Publication statusE-pub ahead of print - 2023

Cite this